Platelet-specific chimeric immunoglobulin and methods of use therefor

Abstract From the Canadian patent

Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa receptor in its complexed form; they block ligand binding to the receptor and prevent platelet aggregation. The immunoglobulins can be used to reduce or prevent occlusion, reocclusion (e.g abrupt closure), stenosis and/or restenosis. In addition the immunoglobulins are useful in, anti-thrombotic therapy when administered alone or in conjunction with thrombolytic agents as well as in thrombus imaging.